A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07195682
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
125
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Cell Carcinoma
Interventions
DRUG:
BMS-986506
Sponsor
Bristol-Myers Squibb